P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
 
-->

Recent Headlines

Friday, Apr 18

Is Parkinson’s an Autoimmune Disease?

Sprifermin Shows Mixed Results in Knee OA

FDA Approves Ragwitek for Short Ragweed Pollen Allergies

New Report Finds About 12 Million Outpatients Misdiagnosed Annually in U.S.

FDA OKs Arzerra (Ofatumumab) as First-Line Treatment With Chlorambucil in Patients With CLL

Thursday, Apr 17

Promising Results Reported for Remogliflozin Etabonate in Mid-Stage Diabetes Trials

New CDC Data Show Declines in Diabetes-Related Complications Among U.S. Adults

Psoriasis Drug Meets Primary Endpoint in Phase II Study

Volasertib Granted ‘Orphan Drug’ Designation for Acute Myeloid Leukemia

New Kind of Trial Speeds Development of Cancer Drugs

Wednesday, Apr 16

New Blood Test Detects Recurrent Breast Cancers

Pivotal Phase III Study Evaluates Veliparib (ABT-888) in Lung Cancer Patients

FDA Approves Tanzeum (Albiglutide) to Treat Type-2 Diabetes

Recombinant Treatment for von Willebrand Disease Meets Primary Efficacy Endpoint in Phase III Trial

Body Mass Index Associated With Breast Cancer, Regardless of Body Shape

Tuesday, Apr 15

Medical Devices for Children Often Tested Only in Adults

Survey: Ivabradine Set to Become ‘Gold Standard’ in Treatment of Chronic Heart Failure

Empagliflozin/Linagliptin Tablet Submitted for FDA Review for Treatment of Type-2 Diabetes in Adults

Grass Pollen Allergy Drug Grastek Gets FDA Green Light

Study: Nearly 10% of U.S. Adults Have Diabetes

Monday, Apr 14

Parkinson’s Drug Rytary (Carbidopa/Levodopa) Resubmitted for FDA Review

Late-Stage Trial Supports Efficacy of Obeticholic Acid in Patients With Biliary Cirrhosis

Diabetes Drug LX4211 Achieves Primary Endpoint in Phase II Trial

Immune Modulator CYT003 Fails Asthma Study

New Drug Application Submitted to FDA for Fixed-Dose Atazanavir/Cobicistat Combo for HIV-1 Patients

Friday, Apr 11

Mydicar Receives ‘Breakthrough Therapy’ Designation as Heart Failure Treatment

Community Demographics Linked to Hospital Readmissions

Cochrane Review: Governments Wasted Money Stockpiling Tamiflu

HCV Combo Therapy Demonstrates Antiviral Activity in Hard-to-Cure Patients

Prostate Cancer Tests Underestimate Disease in Half of Cases

Thursday, Apr 10

Nephrologists Report Decline in Use of ESAs in Hemodialysis and Peritoneal Dialysis Patients Compared With 1 Year Ago

WHO Guidelines Call for Pricey Hepatitis C Drugs

New Polymer–Antibiotic Combo Targets MRSA

Positive Efficacy and Safety Results Reported From Phase III Pediatric Study of Eloctate (rFVIII-Fc) for Hemophilia

Study: Hepatitis C Combo Therapy Cures Up to 90%

Wednesday, Apr 9

Task Force Recommends Low-Dose Aspirin for Women at High Risk for Preeclampsia

Intranasal Ketamine Confers Rapid Antidepressant Effect in Major Depressive Disorder

NIH Study: Spinal Stimulation Helps Paraplegic Patients Regain Voluntary Movement

Experts Offer Guidance on Preventing Catheter-Associated UTIs

FDA Halts Mid-Stage Study of Recombinant Hyaluronidase in Pancreatic Cancer

Tuesday, Apr 8

Handheld Device Uses Blood Sample to Distinguish Asthma From Allergies

Survey: U.S. Neurologists Willing to Accept Safety Risk if New MS Therapies Can Reduce Disability Progression

Supplemental New Drug Application Filed for Ibrutinib (Imbruvica) for Treatment of Leukemia and Lymphoma

Positive Results Reported From Pivotal Phase III Study of Aripiprazole Lauroxil for Treatment of Schizophrenia

Study: U.S. Childhood Obesity Rates Have Increased Since 1999

Monday, Apr 7

Positive Results Reported for Palbociclib Plus Letrozole in Patients With Advanced Breast Cancer

Regulatory Approval Sought for HCV Combo Treatment

Study: Milk Intake May Delay Knee OA in Women

Meningitis B Vaccine Bexsero Receives ‘Breakthrough Therapy’ Designation

FDA Delays Decision on Inhaled Insulin Product Afrezza

Friday, Apr 4

CDC Finds Dramatic Increase in E-Cigarette–Related Calls to Poison Centers

Study: Depression Increases Heart Failure Risk by 40%

Intravitreal Sirolimus Meets Phase III Goal as Uveitis Therapy

Resiniferatoxin Shows Promise as Cancer Pain Treatment

Mixed Results Reported for Talimogene Laherparepvec in Patients With Metastatic Melanoma

Thursday, Apr 3

Survey: Both Physicians and Payers Are Sensitive to Risk of Next-Day Impairment With Insomnia Therapies

Nanoparticles Cause Cancer Cells to Self-Destruct

Fertility Drugs Do Not Increase Long-Term Breast Cancer Risk, Study Finds

CDC Report: Pulmonary Hypertension Deaths Have Increased Over Past Decade

FDA Approves Hand-Held Auto-Injector to Reverse Opioid Overdose

Wednesday, Apr 2

Proton Therapy Limits Prostate Cancer Recurrence

NIH Report: Aspirin Shows Mixed Results in Preventing Pregnancy Loss

Votrient (Pazopanib) Tops Sutent (Sunitinib) in Patient Preference Study

FDA Approves First Sublingual Allergen Extract for Grass Pollen Allergies

Glaxo Walks Away From Lung Cancer Vaccine

Tuesday, Apr 1

Medical Costs Triple for High-Risk Opioid Users

Medicaid Fastest-Growing Managed Health Care Segment

Why Smoking Could Worsen Obesity

Janssen Seeks Approval for Combination HIV Therapy

FDA Advisors Back Two Antibiotics for ABSSSIs

Monday, Mar 31

FDA Approves Hemophilia Treatment Alprolix

Evolocumab Reduces LDL Cholesterol in Phase III Studies

Study: Renal Denervation Doesn’t Lower Blood Pressure

Disappointing Late-Stage Results Reported for Darapladib in Patients With Chronic CHD

Heart Failure Compound LCZ696 Shows Promise in Phase III Trial